2019 Pre-Diabetes (Impaired Glucose Tolerance) Clinical Trials Guide- Companies, Drugs, Phases, Subjects, Current Status and Outlook to 2025

April 2019 | 330 pages | ID: 24C9E1CFBB6EN
VPAResearch

Abstracts

The global clinical trial report- “2019 Pre-Diabetes (Impaired Glucose Tolerance) Clinical Trials Study” provides complete list of trials completed, ongoing and planned for Pre-Diabetes (Impaired Glucose Tolerance). It presents in-depth analysis of Pre-Diabetes (Impaired Glucose Tolerance) clinical trials across markets and companies. The research work is for providing complete understanding into trends in Pre-Diabetes (Impaired Glucose Tolerance).

The report covers a key snapshot of trial trends, enrollment trends, success trends, locations and other trends.

It also segments the Pre-Diabetes (Impaired Glucose Tolerance) clinical trials by-

• Current Trial Status
• Type of the trial
• Sponsor Type
• Enrollment Trends
• Region
• Countries
• Trial Phase

The report also identifies the potential drug candidates under development for treatment of Pre-Diabetes (Impaired Glucose Tolerance)

The research work is prepared through extensive and continuous research on Pre-Diabetes (Impaired Glucose Tolerance) trials from over 1500 sources including company websites, conferences and presentations, scientific journals, country wise and global clinical trial registries, news, health and science departments among others.

Report Scope and Coverage:

• All major trials from 2010 to 2019 and planned trials are included in the report scope.
• Drug candidates currently being researched for administering Pre-Diabetes (Impaired Glucose Tolerance) patients are identified
• The report includes panorama of Pre-Diabetes (Impaired Glucose Tolerance) clinical trials across the globe
• Trial Phase, Current Status, Sponsor Type, Location, trial type and Enrollment details are provided
• Companies and universities focusing on Pre-Diabetes (Impaired Glucose Tolerance) clinical trials are analyzed along with their trial participation (trial title, trial phase and current status)
• Average Enrollment number, insights into enrollment trends, company wise enrollment are included
• Both interventional and observational studies are analyzed
• News and latest developments for the past one year are presented in the report

Contents

1. TABLE OF CONTENTS

1.1 List of Figures
1.2 List of Tables

2. EXECUTIVE SUMMARY

2.1 Pre-Diabetes (Impaired Glucose Tolerance) Clinical Trials Overview, 2019
2.2 Premium Insights into Clinical Trials
  2.2.1 Pre-Diabetes (Impaired Glucose Tolerance) Clinical Trials by Region
  2.2.2 Average Enrollment of Pre-Diabetes (Impaired Glucose Tolerance) Clinical Trials
  2.2.3 Companies participating in Trials
  2.2.4 Drugs under Study for Pre-Diabetes (Impaired Glucose Tolerance) Treatment, 2019

3. REGION WISE PRE-DIABETES (IMPAIRED GLUCOSE TOLERANCE) CLINICAL TRIALS

3.1 Asia Pacific Pre-Diabetes (Impaired Glucose Tolerance) Clinical Trials by Country
3.2 Europe Pre-Diabetes (Impaired Glucose Tolerance) Clinical Trials by Country
3.3 North America Pre-Diabetes (Impaired Glucose Tolerance) Clinical Trials by Country
3.4 Middle East and Africa Pre-Diabetes (Impaired Glucose Tolerance) Clinical Trials by Country
3.5 South and Central America Pre-Diabetes (Impaired Glucose Tolerance) Clinical Trials by Country

4. PRE-DIABETES (IMPAIRED GLUCOSE TOLERANCE) CLINICAL TRIAL TRENDS

4.1 Start Year wise Pre-Diabetes (Impaired Glucose Tolerance) Clinical Trials
4.2 Phase wise Pre-Diabetes (Impaired Glucose Tolerance) Clinical Trials
4.3 Trial Status wise Pre-Diabetes (Impaired Glucose Tolerance) Clinical Trials
4.4 Trial Type wise Pre-Diabetes (Impaired Glucose Tolerance) Clinical Trials

5. PRE-DIABETES (IMPAIRED GLUCOSE TOLERANCE) AVERAGE ENROLLMENT TRENDS

5.1 Average Enrollment in Pre-Diabetes (Impaired Glucose Tolerance) Trials by Year
5.2 Average Enrollment in Pre-Diabetes (Impaired Glucose Tolerance) Trials by Phase
5.3 Average Enrollment in Pre-Diabetes (Impaired Glucose Tolerance) Trials by Status
5.4 Average Enrollment in Pre-Diabetes (Impaired Glucose Tolerance) Trials by Type of Trial

6. COMPANIES PARTICIPATING IN PRE-DIABETES (IMPAIRED GLUCOSE TOLERANCE) CLINICAL TRIALS

6.1 Pre-Diabetes (Impaired Glucose Tolerance) Trials by Sponsor Type
6.2 Pre-Diabetes (Impaired Glucose Tolerance) Average Enrollment by Sponsor Type
6.3 Subjects Recruited by Leading Sponsors

7 TRIAL SNAPSHOTS- PHASE, TYPE, TITLE, LOCATION, START YEAR, COMPLETION YEAR, RECRUITMENT STATUS, ENROLLMENT, PARTICIPATING COUNTRIES, TRIAL LOCATIONS, COMPANY, DRUGS AND OTHER DETAILS

7.1 Pre-Diabetes (Impaired Glucose Tolerance) Trials- Phase
7.2 Pre-Diabetes (Impaired Glucose Tolerance) Trials- Phase
7.3 Pre-Diabetes (Impaired Glucose Tolerance) Trials- Phase
7.4 Pre-Diabetes (Impaired Glucose Tolerance) Trials- Phase

8. APPENDIX

8.1 Report Guidance
8.2 Research Methodology
8.3 Abbreviations
8.4 Definitions
8.5 Sources
8.6 Publisher Expertise

List Of Figures

LIST OF FIGURES

Figure 1: Pre-Diabetes (Impaired Glucose Tolerance) Clinical Trials by Region, 2019
Figure 2: Country wise Clinical Trials, 2019
Figure 3: Country wise Average Enrolment, 2019
Figure 4: Asia Pacific – Country wise Pre-Diabetes (Impaired Glucose Tolerance) Clinical Trials and Enrolment
Figure 5: Europe – Country wise Pre-Diabetes (Impaired Glucose Tolerance) Clinical Trials and Enrolment
Figure 6: Middle East Africa – Country wise Pre-Diabetes (Impaired Glucose Tolerance) Clinical Trials and Enrolment
Figure 7: North America – Country wise Pre-Diabetes (Impaired Glucose Tolerance) Clinical Trials and Enrolment
Figure 8: South and Central America – Country wise Pre-Diabetes (Impaired Glucose Tolerance) Clinical Trials and Enrolment
Figure 9: Pre-Diabetes (Impaired Glucose Tolerance) Clinical Trials by Phase
Figure 10: Pre-Diabetes (Impaired Glucose Tolerance) Clinical Trials by Trial Status
Figure 11: Pre-Diabetes (Impaired Glucose Tolerance) Clinical Trials by Type
Figure 12: Pre-Diabetes (Impaired Glucose Tolerance) Clinical Trials by Sponsor Type
Figure 13: Pre-Diabetes (Impaired Glucose Tolerance) Clinical Trials by Leading Sponsors
Figure 14: Pre-Diabetes (Impaired Glucose Tolerance) Average Enrollment by Phase
Figure 15: Pre-Diabetes (Impaired Glucose Tolerance) Average Enrollment by Trial Status
Figure 16: Pre-Diabetes (Impaired Glucose Tolerance) Average Enrollment by Type
Figure 17: Pre-Diabetes (Impaired Glucose Tolerance)- Average Enrolment by Type of Sponsors
Figure 18: Pre-Diabetes (Impaired Glucose Tolerance)- Enrolment by Leading Sponsors
Figure 19: VPAResearch- Research Methodology

List Of Tables

LIST OF TABLES

Table 1: Pre-Diabetes (Impaired Glucose Tolerance) Clinical Trials Snapshot- 2019
Table 2: Trials by Region, 2019
Table 3: Country wise Clinical Trials and Average Enrolment by Country, 2019
Table 4: Asia Pacific – Country wise Pre-Diabetes (Impaired Glucose Tolerance) Clinical Trials and Enrolment
Table 5: Europe – Country wise Pre-Diabetes (Impaired Glucose Tolerance) Clinical Trials and Enrolment
Table 6: Middle East Africa – Country wise Pre-Diabetes (Impaired Glucose Tolerance) Clinical Trials and Enrolment
Table 7: North America – Country wise Pre-Diabetes (Impaired Glucose Tolerance) Clinical Trials and Enrolment
Table 8: South and Central America – Country wise Pre-Diabetes (Impaired Glucose Tolerance) Clinical Trials and Enrolment
Table 9: Clinical Trials by Phase
Table 10: Clinical Trials by Trial Status
Table 11: Clinical Trials by Type
Table 12: Clinical Trials by Sponsor Type
Table 13: Clinical Trials by Leading Sponsors
Table 14: Pre-Diabetes (Impaired Glucose Tolerance) Average Enrollment by Phase
Table 15: Pre-Diabetes (Impaired Glucose Tolerance) Average Enrollment by Trial Status
Table 16: Pre-Diabetes (Impaired Glucose Tolerance) Average Enrollment by Type
Table 17: Pre-Diabetes (Impaired Glucose Tolerance)- Average Enrolment by Type of Sponsors
Table 18: Pre-Diabetes (Impaired Glucose Tolerance)- Enrolment by Leading Sponsors